Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9FWE

N-VelcroVax HBcAg with SUMO-Affimer inserted at N-terminus (T=3 VLP)

9FWE の概要
エントリーDOI10.2210/pdb9fwe/pdb
EMDBエントリー50832
分子名称N-VelcroVax HBcAg with SUMO-Affimer inserted at N-terminus (1 entity in total)
機能のキーワードvelcrovax, hepatitis b virus, hepatitis b core antigen, affimer, vaccine, recombinant, vlp, antigen display, virus like particle
由来する生物種synthetic construct
タンパク質・核酸の鎖数3
化学式量合計102515.93
構造登録者
Fatema, K.,Snowden, J.S.,Watson, A.,Sherry, L.,Ranson, N.A.,Stonehouse, N.J.,Rowlands, D.J. (登録日: 2024-06-30, 公開日: 2025-02-26, 最終更新日: 2025-03-05)
主引用文献Fatema, K.,Snowden, J.S.,Watson, A.,Sherry, L.,Ranson, N.A.,Stonehouse, N.J.,Rowlands, D.J.
A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture.
Int.J.Biol.Macromol., 305:141152-141152, 2025
Cited by
PubMed Abstract: Nanoparticle presentation systems offer the potential to develop new vaccines rapidly in response to emerging diseases, a public health need that has become increasingly evident in the wake of the COVID-19 pandemic. Previously, we reported a nanoparticle scaffold system termed VelcroVax. This was constructed by insertion of a high affinity SUMO binding protein (Affimer), able to recognise a SUMO peptide tag, into the major immunodominant region of VLPs assembled from a tandem (fused dimer) form of hepatitis B virus (HBV) core protein (HBc). Here we describe an alternative form, termed N-VelcroVax, a VLP vaccine platform assembled from a monomeric HBc protein (N-anti-SUMO Affimer HBc 190) with the Affimer inserted at the N-terminus. In contrast to the tandem form of VelcroVax, N-VelcroVax VLPs were expressed well in E. coli. The VLPs effectively bound SUMO-tagged Junín virus glycoprotein, gp1 as assessed by structural and serological analyses. Cryo-EM characterisation of N-VelcroVax complexed with a SUMO-Junín gp1 showed continuous density attributable to the fused Affimer, in addition to evidence of target antigen capture. Collectively, these data suggest that N-VelcroVax has potential as a versatile next generation vaccine scaffold.
PubMed: 39961558
DOI: 10.1016/j.ijbiomac.2025.141152
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.5 Å)
構造検証レポート
Validation report summary of 9fwe
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon